Literature DB >> 8756375

Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsy.

T Onda1, H Yoshikawa, H Yokota, T Yasugi, Y Taketani.   

Abstract

BACKGROUND: In staging epithelial ovarian carcinoma, it is necessary to assess the presence of lymph node metastases. However, the essential sites of selective lymph node biopsy have yet to be determined.
METHODS: The distribution of metastatic aortic and pelvic lymph nodes was studied in 48 patients with positive lymph nodes of 110 patients with ovarian carcinoma who underwent systematic lymphadenectomy of the aortic and pelvic regions extending to the level of the renal vessels. For purpose of analysis, the lymph nodes were classified into five subgroups: the aortic lymph nodes above the inferior mesenteric artery (A1), the aortic lymph nodes below the inferior mesenteric artery (A2), the common iliac and sacral lymph nodes (P1), the internal and external iliac and obturator lymph nodes (P2), and the suprainguinal (the lowest external iliac) lymph nodes (P3).
RESULTS: The incidence of metastases to A1, A2, P1, P2, and P3 was 79%, 71%, 46%, 77%, and 40%, respectively. Provided that 2 of the 5 lymph node subgroups were selected for biopsy, the combination of A1 and P2 gave the best results in sensitivity (94% [45 of 48 patients]) and negative (95% [62 of 65 patients]) predictive value for detection of lymph node metastases.
CONCLUSIONS: These data indicate that aortic lymph nodes above the inferior mesenteric artery and the internal and external iliac and obturator lymph nodes are essential sites for selective lymph node biopsy in staging epithelial ovarian carcinoma.

Entities:  

Mesh:

Year:  1996        PMID: 8756375     DOI: 10.1002/(SICI)1097-0142(19960815)78:4<803::AID-CNCR17>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

Review 1.  Management of retroperitoneal lymph nodes in the treatment of ovarian cancer.

Authors:  Kimio Ushijima
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

2.  Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group.

Authors:  Takafumi Oshita; Hiroaki Itamochi; Ryuichiro Nishimura; Fumitaka Numa; Kazuhiro Takehara; Masamichi Hiura; Hirotoshi Tanimoto; Jun Noma; Ryoji Hayase; Akihiro Murakami; Hideo Fujimoto; Yasunobu Kanamori; Fuminori Kitada; Keiji Shitsukawa; Makoto Nagaji; Yukihisa Minagawa; Michihisa Fujiwara; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2012-10-17       Impact factor: 3.402

3.  Lymph node metastasis detection of ovarian cancer by porphyrin fluorescence photodetection: case report.

Authors:  Peter Hillemanns; Jessica Reiff; Herbert Stepp; Philipp Soergel
Journal:  Lasers Med Sci       Date:  2007-01-09       Impact factor: 3.161

4.  Perimenopausal ovarian carcinoma patient with subclavian node metastasis proven by immunohistochemistry.

Authors:  Hee Jeong Jeong; Hyun Joo Kim; Eun Hee Lee; Hyoun Wook Lee; Min Kyu Kim
Journal:  J Menopausal Med       Date:  2014-04-28

Review 5.  Lymphatic Vessel Network Structure and Physiology.

Authors:  Jerome W Breslin; Ying Yang; Joshua P Scallan; Richard S Sweat; Shaquria P Adderley; Walter L Murfee
Journal:  Compr Physiol       Date:  2018-12-13       Impact factor: 9.090

6.  Elevated expression of MAC30 predicts lymph node metastasis and unfavorable prognosis in patients with epithelial ovarian cancer.

Authors:  Shanshan Yang; Huiyan Li; Yunduo Liu; Xiaoming Ning; Fanling Meng; Min Xiao; Deying Wang; Ge Lou; Yunyan Zhang
Journal:  Med Oncol       Date:  2012-12-18       Impact factor: 3.064

Review 7.  Potential therapeutic strategies for lymphatic metastasis.

Authors:  Bernadette M M Zwaans; Diane R Bielenberg
Journal:  Microvasc Res       Date:  2007-09-19       Impact factor: 3.514

Review 8.  [The role of radical lymphadenectomy. Experiences from the AGO Ovarian Cancer Study Group].

Authors:  P Wimberger; R Kimmig
Journal:  Urologe A       Date:  2009-01       Impact factor: 0.639

9.  Sentinel node in ovarian cancer: study protocol for a phase 1 study.

Authors:  Marjolein Kleppe; Toon Van Gorp; Brigitte F M Slangen; Arnold J Kruse; Boudewijn Brans; Ivo N A Pooters; Koen K Van de Vijver; Roy F P M Kruitwagen
Journal:  Trials       Date:  2013-02-15       Impact factor: 2.279

10.  Prognostic factors in early-stage ovarian cancer.

Authors:  Germana Tognon; Mario Carnazza; Monica Ragnoli; Stefano Calza; Federico Ferrari; Angela Gambino; Valentina Zizioli; Sara Notaro; Benedetta Sostegni; Enrico Sartori
Journal:  Ecancermedicalscience       Date:  2013-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.